Clinical trial
Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic…
NCT00100750 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00100750 |
|---|---|
| Title | Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer |
| Official title | Gemcitabine and R115777 Combination Therapy for Metastatic Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Breast Carcinoma, Stage IV Breast Cancer |
| Intervention type | Drug, Other |
| Interventions | Gemcitabine Hydrochloride, Tipifarnib, Laboratory Biomarker Analysis |
| Enrollment | 31 |
| Start date | Sep 1, 2005 |
| Primary completion | Oct 1, 2007 |
| Completion | Jan 1, 2010 |
| First posted | Jan 7, 2005 |
| Last update posted | Jan 13, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: